Also, CL4 counteracted the induction of expression of the serine protease inhibitor (SERPINE2) (Fig. 2e), a gene reported to be amplified in tumors with marked VM30 and recently shown to be crucial in programming aggressive breast cancer cells for VM9. Here, SERPINE2 is linked to breast carcinoma.